当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Mary Lynn
The application of proteomic methods to the study of diseases is growing at an ever-increasing rate, and it has begun to fill in significant knowledge gaps regarding the etiology of disease and the development of efficient methods for the early detection and treatment of diseases. Mass spectrometry and protein separation methods like two-dimensional gel electrophoresis and liquid chromatography are examples of biophysical techniques that are an essential component of the advanced proteomic methods that are currently in use. Determining altered protein expression not only at the whole-cell or tissue levels, but also in subcellular structures, protein complexes, and biological fluids is one way that biophysical proteomic methods can be used to study disease. Additionally, these methods are being used to discover novel disease biomarkers, investigate disease pathogenesis, develop novel diagnostic methods, and identify novel therapeutic targets. Through more efficient methods for assessing a drug's therapeutic effects and toxicity, proteomic methods also have the potential to accelerate drug development. In order for biophysical proteomic methods to be more widely accepted and have a greater impact, this article discusses how they can be used to identify cardiovascular disease and other diseases, as well as their limitations and potential future research directions [1, 2].